Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets
- PMID: 19782703
- DOI: 10.1016/j.jneumeth.2009.09.023
Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets
Abstract
A major challenge for the treatment of cancers, such as glioblastoma multiforme (GBM), has been resistance to radiation and cancer chemotherapeutics. Short interfering RNA (siRNA) based screening may facilitate the identification of genes and pathways essential for cancer cell survival and could enable a more targeted therapeutic approach for the treatment of GBM. Although the commercial availability of siRNA libraries has expanded greatly, detailed methods for the implementation and analysis of genome-scale screens are largely lacking. To annotate the essential genes and pathways for glioma cell survival, we designed, optimized, and implemented a high-throughput siRNA screen in the highly drug and radiation resistant T98G glioma cell line. We developed a rapid, readily available, and simple strategy to optimize siRNA transfection assays in a 384-well plate format based on immunofluorescence studies and inhibition of the non-essential, endogenous gene lamin A/C. We used these transfection conditions to successfully screen a library of 1056 siRNAs targeting 352 unique human genes in a cell-based one gene per well format to identify the genes essential for glioma cell survival and assess the quality of the screening conditions prior to large-scale screening. After developing and applying a median-based outlier detection algorithm for post-screen analysis, we identified the Ras oncogene family member RAN as an essential gene for glioma cell survival. Successful implementation and analysis of this siRNA screen validates our transfection optimization approach and provides guidance for the rapid development of high-throughput siRNA screens in human glioma cells.
Similar articles
-
Median absolute deviation to improve hit selection for genome-scale RNAi screens.J Biomol Screen. 2008 Feb;13(2):149-58. doi: 10.1177/1087057107312035. Epub 2008 Jan 23. J Biomol Screen. 2008. PMID: 18216396
-
An efficient and fully automated high-throughput transfection method for genome-scale siRNA screens.J Biomol Screen. 2008 Feb;13(2):142-8. doi: 10.1177/1087057107312032. Epub 2008 Jan 23. J Biomol Screen. 2008. PMID: 18216392
-
High-throughput RNAi screening for the identification of novel targets.Methods Mol Biol. 2013;986:89-95. doi: 10.1007/978-1-62703-311-4_6. Methods Mol Biol. 2013. PMID: 23436407
-
Oncology studies using siRNA libraries: the dawn of RNAi-based genomics.Oncogene. 2004 Nov 1;23(51):8384-91. doi: 10.1038/sj.onc.1208072. Oncogene. 2004. PMID: 15517020 Review.
-
Technology evaluation: SAGE, Genzyme molecular oncology.Curr Opin Mol Ther. 2001 Feb;3(1):85-96. Curr Opin Mol Ther. 2001. PMID: 11249736 Review.
Cited by
-
Systematic analysis of RNAi reports identifies dismal commonality at gene-level and reveals an unprecedented enrichment in pooled shRNA screens.Comb Chem High Throughput Screen. 2013 Nov;16(9):665-81. doi: 10.2174/13862073113169990045. Comb Chem High Throughput Screen. 2013. PMID: 23848309 Free PMC article.
-
ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.J Pharmacol Exp Ther. 2012 Jun;341(3):859-72. doi: 10.1124/jpet.112.191536. Epub 2012 Mar 5. J Pharmacol Exp Ther. 2012. PMID: 22393246 Free PMC article.
-
Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay.Radiat Res. 2012 Sep;178(3):150-9. doi: 10.1667/rr2810.1. Epub 2012 Jul 2. Radiat Res. 2012. PMID: 22747550 Free PMC article.
-
YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.Mol Cancer Ther. 2013 Mar;12(3):326-38. doi: 10.1158/1535-7163.MCT-12-0901. Epub 2013 Jan 16. Mol Cancer Ther. 2013. PMID: 23325792 Free PMC article.
-
Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines.Mol Carcinog. 2017 Apr;56(4):1251-1265. doi: 10.1002/mc.22587. Epub 2016 Nov 22. Mol Carcinog. 2017. PMID: 27805285 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous